Sorry, there was a problem.

An unexpected error occurred and your request couldn't be handled. Please call a Dignity Health representative at
(844) 274-8497
OR
Chat with us here.

Reference code:

Clinical Trials


The University of Arizona Cancer Center at Dignity Health St. Joseph’s Hospital and Medical Center leads several clinic trials within our Phoenix cancer center.

Below is a list of our active trials. Select the study name for specific information about that trial. For more information about how to participate in any of the clinical trials listed below, contact the Clinical Trials Office at 855.622.6845.

 

BASAL CELL CARCINOMA

Panayiotis Savvides, MD

PHXE-17-0101-80-15

A Phase 2 Study of REGN2810, A Fully Human Monoclonal Antibody to Programmed Death-1, in Patients with Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy

 

 

BLADDER CANCER

Jue Wang, MD

PHXE-16-0204-80-15

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

 

 

BREAST CANCER

Albert Wendt, MD

PHXA-15-0013-10-15

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

 

Albert Wendt, MD

PHXE-16-0167-10-15

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

 

Albert Wendt, MD

PHXE-17-0356-80-15

MonarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, BreastCancer

 

Albert Wendt, MD

PHXA-17-0242-71-15

Aerobic Interval Exercise Preconditioning to Prevent Cardiometabolic and Neuropsychological Complications of Anthracycline Based Breast Cancer Chemotherapy

 

Lora Hebert, MD

PHXE-17-0351-10-15

A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment without Surgery.

 

 

CERVICAL CANCER

John Farley, MD

PHXA-16-0094-80-15

Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV

 

 

ENDOMETRIAL CANCER

John Farley, MD

PHXE-16-0179-80-15

A Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor), MLN0128+MLN1117 (a PI3Ká Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MLN0128 in Women With Advanced, Recurrent, or Persistent Endometrial Cancer

 

 

HEAD AND NECK CANCER

Panayiotis Savvides, MD

PHXB-17-0072-70-15

Clinical evaluation of everolimus (a rapamycin analog) in restoring salivary gland function to patients treated with radiotherapy for head and neck cancer

 

 

KIDNEY CANCER

Jue Wang, MD

PHXE-17-0114-10-15

A Phase 3 RandOmized Study Comparing PERioperative Nivolumab Vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)

 

 

LIVER CANCER

Nitika Thawani, MD

PHXB-13RT127

Randomized Phase III Study of Sorafenib versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma

 

 

LUNG CANCER

Panayiotis Savvides, MD

PHXB-15-0011-80-15

SHERLOC: A Phase 2 Study of MM-121 in Combination with Docetaxel versus Docetaxel Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

 

 

PROSTATE CANCER

Jue Wang, MD

PHXB-15-0015-80-15

A Prospective Observational Cohort Study of Patients with Castration-Resistant Prostate Cancer (CRPC) in the United States

 

 

OVARIAN CANCER

John Farley, MD

PHXA-15-0002-10-15

Can Diet and Physical Activity Modulate Ovarian Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?

 

John Farley, MD

PHXE-16-0213-80-15

A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

 

 

Learn More

For more information or to participate, call the Clinical Trials Office at 855.622.6845.